Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKAB2 | O43741 | 5/20 | 0.47 |
| ▸ | PRKAG1 | P54619 | 5/20 | 0.47 |
| ▸ | PRKAA2 | P54646 | 5/20 | 0.47 |
| ▸ | PRKAA1 | Q13131 | 5/20 | 0.47 |
| ▸ | PRKAG3 | Q9UGI9 | 5/20 | 0.47 |
| ▸ | PRKAG2 | Q9UGJ0 | 5/20 | 0.47 |
| ▸ | PRKAB1 | Q9Y478 | 5/20 | 0.47 |
| ▸ | MARS1 | P56192 | 5/20 | 0.42 |
| ▸ | CNR1 | P21554 | 3/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.41 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14713225 | 0.88 | CNR1 (0.43) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL1258893 | 0.84 | MARS1 (0.52) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL1260378 | 0.84 | CNR1 (0.49) | MARS1CNR1SRD5A2 | |
| SCHEMBL2570109 | 0.81 | ESR1 (0.51) | MARS1CNR1SRD5A2 | |
| SCHEMBL1127599 | 0.79 | CNR1 (0.49) | CNR1 | |
| SCHEMBL2567965 | 0.77 | CNR1 (0.53) | CNR1 | |
| SCHEMBL1990424 | 0.75 | CNR1 (0.51) | CNR1 | |
| SCHEMBL1983795 | 0.74 | CNR1 (0.46) | CNR1 | |
| SCHEMBL1986687 | 0.73 | GABRA2 (0.54) | MARS1CNR1 | |
| SCHEMBL1260411 | 0.73 | CNR1 (0.43) | CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8383666-B2 | Pyrrole derivatives, preparation of same and therapeutic application thereof | SANOFI (FR) | 2013-02-26 | — | — | US | disclosed |
| US-20110144157-A1 | PYRROLE DERIVATIVES, PREPARATION OF SAME AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2011-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144157-A1 | PYRROLE DERIVATIVES, PREPARATION OF SAME AND THERAPEUTIC APPLICATION THEREOF | ARG2, PYCR1, ARG1 | PRKAB2 3197/4885PRKAG1 4110/4885PRKAA2 4081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.